<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600817</url>
  </required_header>
  <id_info>
    <org_study_id>TJ107001GBM201</org_study_id>
    <nct_id>NCT04600817</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)</brief_title>
  <official_title>A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and&#xD;
      Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed&#xD;
      Standard Concurrent Chemoradiotherapy (CCRT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with average of ALC at 3w after first TJ107 dose and at pre-dose 3rd TMZ ≥1.5X109/L</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Newly Diagnosed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TJ107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TJ107Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ107</intervention_name>
    <description>QW8</description>
    <arm_group_label>TJ107</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ107 placebo</intervention_name>
    <description>QW8</description>
    <arm_group_label>TJ107Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form (ICF)&#xD;
&#xD;
          2. Age ≥ 18 years and ≤70 years.&#xD;
&#xD;
          3. Gross total resection equal to or greater than 80% based on post-op MRI, compared to&#xD;
             pre-op MRI (Patients requiring biopsy only is not eligible)&#xD;
&#xD;
          4. Patients newly diagnosed with glioblastoma either radiologically or pathologically and&#xD;
             completed concurrent chemo-radiotherapy (CCRT) with plan to receive adjuvant&#xD;
             temozolomide therapy with curative intent&#xD;
&#xD;
          5. Adequate hematologic and end organ function, defined by the following laboratory&#xD;
             results obtained within 14 days prior to the randomization.1) Absolute lymphocyte&#xD;
             count (ALC) ≤1×109/L. 2) Absolute neutrophil count (ANC) ≥ 1.5×109/L. 3) Platelet&#xD;
             count ≥ 100×109/L (without transfusion within 14 days prior to Cycle 1, Day 1). 4)&#xD;
             Hemoglobin ≥ 9 g/dL Patients may be transfused or may receive erythropoietic treatment&#xD;
             as per local standard of care. 5) Total bilirubin ≤ 1.5 × the upper limit of normal&#xD;
             (ULN). 6) AST and ALT ≤ 3 × ULN. 7) Alkaline phosphatase ≤ 2.5 × ULN (For subject with&#xD;
             proven liver or bone metastasis, alkaline phosphatase ≤ 5 × ULN is allowed). 8) Serum&#xD;
             albumin ≥ 2.5 g/dL. 9) Serum creatinine ≤ 1.5 mg/dL. 10) Prothrombin time (PT) and&#xD;
             activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN. This applies only to&#xD;
             patients who are not receiving therapeutic anticoagulation. Patients receiving&#xD;
             therapeutic anticoagulation should be on a stable dose&#xD;
&#xD;
          6. Karnofsky score ≥ 60&#xD;
&#xD;
          7. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          8. For women of childbearing potential*: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods that result in a failure rate&#xD;
             of &lt; 1% per year from the date of informed consent to at least 3 months after the last&#xD;
             dose of study drugs. For men: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and agreement to refrain from donating&#xD;
             sperm, as defined below: With female partners of childbearing potential or pregnant&#xD;
             female partners, men must remain abstinent or use a condom during the treatment period&#xD;
             and for at least 3 months after the last dose of study treatment (TJ107) and 6 months&#xD;
             after the last dose of temozolomide to avoid exposing the embryo. Men must refrain&#xD;
             from donating sperm during this same period. The reliability of sexual abstinence&#xD;
             should be evaluated in relation to the duration of the clinical trial and the&#xD;
             preferred and usual lifestyle of the patient. Periodic abstinence and withdrawal are&#xD;
             not acceptable methods of contraception.&#xD;
&#xD;
               -  A woman is of childbearing potential if she is postmenarcheal, has not reached a&#xD;
                  postmenopausal state (≥ 12 continuous months of amenorrhea with no identified&#xD;
                  cause other than menopause), and has not undergone surgical sterilization&#xD;
                  (removal of ovaries and/or uterus).&#xD;
&#xD;
               -  Examples of contraceptive methods with a failure rate of &lt; 1% per year include&#xD;
                  bilateral tubal ligation, male sterilization, and established proper use of&#xD;
                  hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine&#xD;
                  devices, and copper intrauterine devices.&#xD;
&#xD;
               -  Hormonal contraceptive methods must be supplemented by a barrier method plus&#xD;
                  spermicide.&#xD;
&#xD;
               -  The reliability of sexual abstinence should be evaluated in relation to the&#xD;
                  duration of the clinical trial and the preferred and usual lifestyle of the&#xD;
                  patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects receiving 21 days hypofractionated radiotherapy due to clinical condition&#xD;
&#xD;
          2. Multifocal glioma (≥3 lesions)&#xD;
&#xD;
          3. Patients with primary subtentorial glioblastoma multiforme&#xD;
&#xD;
          4. Patients who have evidence of leptomeningeal disease&#xD;
&#xD;
          5. Patients on corticosteroid treatment have not a stable or decreasing dose for 14 days&#xD;
             before randomization.&#xD;
&#xD;
          6. Pregnancy, lactation, or breastfeeding (with lactation or breastfeeding required&#xD;
             during the study period)&#xD;
&#xD;
             *Serum pregnancy test for women of childbearing potential (including women who have&#xD;
             had a tubal ligation) must be performed and documented as negative within 14 days&#xD;
             prior to randomization&#xD;
&#xD;
          7. Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction within the previous 3 months, unstable&#xD;
             arrhythmias, and/or unstable angina&#xD;
&#xD;
          8. Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, and inherited liver disease or current alcohol abuse&#xD;
&#xD;
          9. Poorly controlled Type 2 diabetes mellitus defined as a screening hemoglobin A1C ≥ 8%&#xD;
             or a fasting plasma glucose ≥ 160 mg/dL (or 8.8 mmol/L)&#xD;
&#xD;
         10. Anticipation of need for a major surgical procedure (requiring general anesthesia)&#xD;
             during the study period&#xD;
&#xD;
         11. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension (defined by blood pressure higher than 150/90mmHg despite effective&#xD;
             anti-hypertensive treatments) and active bleeding diatheses, which in the&#xD;
             investigator's opinion makes it undesirable for the patient to participate in trial or&#xD;
             which would jeopardize compliance with the protocol&#xD;
&#xD;
         12. Any anti-cancer therapy, whether investigational or approved, including chemotherapy,&#xD;
             immunotherapy, gene therapy, cancer vaccine, cell therapy, cytokines, hormonal&#xD;
             therapy, and/or radiotherapy) received after standard concurrent chemo-radiotherapy&#xD;
             (CCRT)&#xD;
&#xD;
         13. Persisting toxicity related to prior therapy (NCI CTCAE v. 5.0 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety&#xD;
             risk based on investigator's judgment are acceptable&#xD;
&#xD;
         14. Malignancies other than disease under study within 5 years prior to randomization&#xD;
             except for those with a negligible risk of metastasis or death (such as adequately&#xD;
             treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized&#xD;
             prostate cancer, or ductal carcinoma in situ)&#xD;
&#xD;
         15. Uncontrolled hypercalcemia (ionized Calcium &gt; 1.5 mmol/L or Calcium &gt; 12 mg/dL or&#xD;
             adjusted serum Calcium ≥ ULN) or symptomatic hypercalcemia requiring bisphosphate or&#xD;
             denosumab&#xD;
&#xD;
             *Patients without history of clinically significant hypercalcemia, receiving either&#xD;
             bisphosphonate or denosumab prophylactically is eligible&#xD;
&#xD;
             ** Denosumab receiving patients should agree to switch to bisphosphate, and not&#xD;
             contraindicated for bisphosphate use are eligible&#xD;
&#xD;
         16. Patients with active virus infection requiring systemic treatment at screening 1)&#xD;
             Positive test for HIV infection 2) Active HBV hepatitis: positive for HBsAg and&#xD;
             HBV-DNA, if HBsAg positive but HBV-DNA negative during the screening can participate&#xD;
             in the study.3) Active HCV hepatitis: positive for hepatitis C virus (HCV) antibody&#xD;
             and HCV RNA. But the subject can be enrolled with serum anti-HCV positive and HCV RNA&#xD;
             negative.&#xD;
&#xD;
         17. Patients with autoimmune disease requiring treatment at the time of screening&#xD;
             (appendix 3. List of autoimmune disease)1) Patients with adrenal or pituitary&#xD;
             insufficiency requiring physiological dose of corticosteroid such as tyrosine,&#xD;
             insulin. 2) Patients with leukoplakia, resolved pediatric asthma, atopic dermatitis,&#xD;
             type 1 diabetic, hypothyroidism due to autoimmune disease only requiring hormone&#xD;
             replacement therapy, psoriasis not requiring systemic treatment, and other disease&#xD;
             status that recurrence nor exacerbations are not expected unless there is external&#xD;
             contributing factors&#xD;
&#xD;
         18. Administration of a live, attenuated vaccine within 14 days before randomization or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study.1)&#xD;
             Measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guérin,&#xD;
             BCG, herpes zoster, typhoid vaccines. 2) Seasonal influenza vaccine in injection&#xD;
             formulation are generally not live vaccine, thus are allowed. Yet intra-nasal&#xD;
             influenza vaccine such as Flumist® is attenuated live vaccine, thus is not allowed&#xD;
&#xD;
         19. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
         20. Severe infections within 2 weeks prior to randomization, including but not limited to&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia&#xD;
&#xD;
         21. Prior allogeneic bone marrow transplantation or prior solid organ transplantation&#xD;
&#xD;
         22. Treatment with systemic immunosuppressive medications (including daily prednisone &gt;&#xD;
             30mg, dexamethasone &gt; 5mg, or equivalent dose of corticosteroid, cyclophosphamide,&#xD;
             azathioprine, methotrexate, thalidomide, and TNF-α antagonists but not limited to)&#xD;
             within 2 weeks prior to randomization. 1) Patients who acutely receives low dose&#xD;
             immunosuppressive medication (e.g. daily prednisone ≤ 30 mg or daily dexamethasone ≤ 5&#xD;
             mg) can be enrolled upon approval from study medical monitor. 2) The use of inhaled&#xD;
             corticosteroids (e.g., fluticasone for chronic obstructive pulmonary disease) is&#xD;
             allowed. 3) The use of oral mineralocorticoids (e.g., fludrocortisone for patients&#xD;
             with orthostatic hypotension) is allowed.&#xD;
&#xD;
         23. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),&#xD;
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing&#xD;
             pneumonia, etc.), or evidence of active pneumonitis * History of radiation pneumonitis&#xD;
             in the radiation field (fibrosis) is allowed.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenbin Li</last_name>
    <phone>15301377998</phone>
    <email>neure55@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhuang Kang</last_name>
    <phone>15011281069</phone>
    <email>kzhaoren1984@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiping Li</last_name>
      <phone>138 0883 4238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Su</last_name>
      <phone>139 3619 8606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangyuan Hu</last_name>
      <phone>138 8600 0095</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping You</last_name>
      <phone>137 7069 4258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingen Zhu</last_name>
      <phone>138 0354 6020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haozhe Piao</last_name>
      <phone>189 0091 7766</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunhui Liu</last_name>
      <phone>189 4025 1313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hechun Xia</last_name>
      <phone>139 9510 9559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital of The Fourth Military Medical University of Chinese PLA</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Wang</last_name>
      <phone>133 1923 2049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbin Li</last_name>
      <phone>15301377998</phone>
      <email>neure55@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhuang Kang</last_name>
      <phone>15011281069</phone>
      <email>kzhaoren1984@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbing Ma</last_name>
      <phone>137 0136 4566</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqiong Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Run Cai</last_name>
      <phone>130 7234 1313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingsong Wu</last_name>
      <phone>137 0170 7118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Huanhu Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
      <phone>130 7220 1699</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenliang Li</last_name>
      <phone>186 2222 1152</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>POONWai Sang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

